Lantern Pharma Announces Transaction to Evaluate BioNumerik’s Tavocept®

DALLAS–(EON: Enhanced Online News)–Lantern Pharma, Inc. (Dallas, TX, US) and BioNumerik Pharmaceuticals, Inc. of San Antonio, Texas have entered into an exclusive agreement for Lantern Pharma to evaluate BioNumerik’s Tavocept^® for human therapeutic indications using Lantern’s 5-M theranostic platform. Tavocept is an investigational new drug candidate from BioNumerik’s portfolio that has shown potential for both oncology and non-oncology indications. Lantern Pharma is a Precision Oncology Medicine company focused on using its proprietary 5-M platform to identify specific drug sensitivity signatures for patient tumor types. The Tavocept transaction demonstrates Lantern’s commitment to the development of precision cancer drugs by employing its cutting-edge companion 5-M theranostics platform with the objective of providing more precise and therefore more effective treatments to patients sooner.
Dr. Arun Asaithambi of Lantern Pharma, commented: “We believe Lantern Pharma’s approach can be successfully applied to identify new value opportunities for drug candidates with promising potential that have encountered development challenges. We are excited about Tavocept and the potential to enhance its therapeutic potency through the application of our 5-M approach.”
“We believe Tavocept has important potential to be of benefit to patients, and we are excited to be working with Lantern Pharma to examine possible ways to realize and expand that potential,” saidThomas W. Lyles, Jr., President of BioNumerik Pharmaceuticals, Inc.
About Lantern Pharma:
Lantern Pharma is leading a wave of innovation in cancer treatment aimed at bringing the best therapies to patients who are most likely to respond. Lantern Pharma is pioneering a precision medicine approach to cancer by tailoring promising drug programs to the right patients. Lantern Pharma has three investigational drug candidates at the clinical and pre-clinical stage. The company’s proprietary 5-M Theranostic platform uses biomarker based molecular genetic screening to identify tumor specific drug sensitivity signatures to help identify those drugs that are most likely to have enhanced potency for a particular patient’s tumor, thereby facilitating the ability to more quickly treat those patients who are likely to benefit most from the identified treatment.
About BioNumerik:
BioNumerik Pharmaceuticals, Inc. is focused on the development and commercialization of novel drugs for the treatment of cancer and cancer supportive care. BioNumerik currently has two investigational drug candidates at the clinical development stage.